Australian Clinical Labs Limited
ASX: ACL
ACL restructuring its operations.
(Source: TradingView) 3-Month Performance Profile of ACL compared to the S&P/ASX 200 (XJO).
In the first half of FY2025, Australian Clinical Labs reported revenue of AUD 369.2 million, marking a 9.5% increase compared to the same period last year. Net profit rose significantly by 136% to AUD 11.8 million. The company
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
